AbbVie pulls out of an Alzheimer's deal with Alector

8 July 2022

US biotech Alector (Nasdaq: ALEC) saw its shares dip 2.8% to $11.16 in morning trading, after it revealed n a filing with the Securities and Exchange Commission that its licensing partner AbbVie (Nasdaq: ABBV) was pulling of a collaboration on Alzheimer’s disease.

Alector, in collaboration with AbbVie Biotechnology, has been developing AL003 to treat patients with Alzheimer’s disease as one of two programs under the co-development and option agreement, dated as of October16, 2017, between the parties.

Under the terms of that accord, AbbVie paid Alector an upfront $205 million, with the potential for more in milestones.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK